U.S. ITC Issues Limited Exclusion and Cease and Desist Orders Over Ventria Patent

The U.S. International Trade Commission (ITC) has issued a limited exclusion order prohibiting the unlicensed entry of infringing plant-derived recombinant human serum albumins (rHSA) and products containing the same.

Cease and desist orders have also been put out related to this issue.

These orders come at the tail end of an investigation related to a complaint that was filed on behalf of Ventria Bioscience in January 2021 claiming infringement of two patents. The ITC orders apply to only one of the patents.

The companies that were targeted in the investigation were Healthgen of Wuhan, China; ScienCell of Carlsbad, Calif.; Aspira of Milpitas, Calif.; and eEnzyme of Gaithersburg, Md.

Only Healthgen participated in the investigation while the three other companies were found in default.